用一线生物治疗的克罗恩病患者实现生化缓解的最佳时间框架:一项回顾性多中心研究
Ji Eun Na1, Yong Eun Park1, Jongha Park1
1Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.
Medicine
|October 28, 2024
概括
大多数是克朗氏病.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 在克罗恩病 (CD) 中预测治疗反应对于有效的生物疗法至关重要.
- C-反应蛋白 (CRP) 的正常化是一个关键指标,但其速度和最佳时间尚不清楚.
研究的目的:
- 确定在开始生物治疗的CD患者中实现CRP正常化的速度和最佳时间框架.
- 确定与早期CRP正常化相关的临床结果和因素.
主要方法:
- 对183名中度至重度CD患者进行了回顾性多中心研究 (2012年1月至2023年7月).
- 主要结果:CRP正常化的速度和时间框架.
- 二次结果:临床结果和早期正常化预测因素.
主要成果:
- 67.2%的患者在平均3.8个月内实现了CRP正常化.
- 不同的生物制剂之间正常化速率或时间没有显著差异.
- CRP正常化持续时间与药物停用减少相关 (AUC 0.64).
- 早期正常化受益于5-氨酸治疗和高白蛋白水平;结构性疾病行为不太可能实现早期正常化.
结论:
- 大多数CD患者在开始生物治疗后大约4个月内出现CRP正常化.
- 实现CRP正常化是克罗恩病管理的可行和重要目标.
- 诸如药物和疾病行为等因素会影响CRP正常化的速度.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Inflammatory Bowel Disease IV: Pharmacological Management
117
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
322
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
322
Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124


